SCHEMBL6628077

SCHEMBL6628077

CC(C)(C)OC(=O)CCCCCCCOc1cccc2c1C(=O)NC2=O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLM Q9NP87 2/20 0.40
POLK Q9UBT6 2/20 0.40
POLL Q9UGP5 2/20 0.40
POLH Q9Y253 2/20 0.40
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PRKCA P17252 6/20 0.37
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
KCNA3 P22001 1/20 0.36
CASP3 P42574 2/20 0.35
PPARG P37231 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
KCNA5 P22460 1/20 0.35
ELANE P08246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4593117 0.79 PRKCA (0.45) POLMPOLKPOLLPOLHKDM4E
SCHEMBL23045114 0.75 KDM4E (0.48) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL29532107 0.74 TRPM2 (0.41) DDB1CRBN
SCHEMBL19709723 0.74 CRBN (0.67) DDB1CRBN
SCHEMBL19709560 0.74 CRBN (0.67) DDB1CRBN
SCHEMBL10776993 0.74 CDK2 (0.43) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL7648225 0.74 CYP2A6 (0.43) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL9735524 0.73 KDM4E (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL9596671 0.73 KCNA3 (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL4663980 0.73 EPHX2 (0.40) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889042-B1 RADICICOL DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2004-05-06 EP disclosed
US-20040053990-A1 Radicicol derivatives KYOWA HAKKO KOGYO CO., LTD (JP) 2004-03-18 US disclosed
US-6635662-B2 A 2-oxime derivative; antitumor and -carcinogenic agents; immunosuppressents; osteoporosis; enzyme inhibitors of tyrosine kinase activity KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-21 US disclosed
US-6316491-B1 INHIBITORS OF TYROSINE KINASE USED AS ANTITUMOR OR IMMUNOSUPPRESSION AGENTS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-11-13 US disclosed
US-20010027208-A1 Radicicol derivatives INO YOJI (JP) 2001-10-04 US disclosed
US-6239168-B1 ANTITUMOR AGENTS, IMMUNOSUPPRESSANTS; TYROSINE KINASE INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2001-05-29 US disclosed
EP-0889042-A1 RADICICOL DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 1999-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053990-A1 Radicicol derivatives ROS1, LYN, SRC POLM 2456/4885POLK 2809/4885POLL 2408/4885
US-20010027208-A1 Radicicol derivatives ROS1, LYN, SRC POLM 2511/4885POLK 2873/4885POLL 2440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.